Search - tctmd.com

Displaying 1 - 20 of 23

Sort: Relevancy | Date

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

$Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)$

Presentation ACC 2024

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Presenter: Rasha K. Al-Lamee

April 08, 2024

News Conference News TCT 2023

Intermittent Coronary Sinus Occlusion Fails to Cut Infarct Size in STEMI

Yael L. Maxwell

November 06, 2023

NY State to Exclude Emergency PCI Cases From Public Outcomes Reports

News Daily News

NY State to Exclude Emergency PCI Deaths From Physician-Level Public Reports

Todd Neale

January 04, 2023

News Conference News ESC 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

Michael O'Riordan

September 07, 2022

News Daily News

Gatekeeper CTA Strategy in Stable Chest Pain Still Needs Honing

Yael L. Maxwell

March 08, 2021

News Conference News ESC 2020

New European NSTE ACS Guidelines Embrace hs-Troponin, CTA, NOAC Trials

Caitlin E. Cox

September 03, 2020

News Daily News

July 2020 News Roundup

L.A. McKeown

July 01, 2020

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

News Daily News

Best Strategy Questioned for NSTE ACS Patients With Prior CABG

Shelley Wood

August 05, 2019

News Daily News

Staged PCI or Complete Revasc? Physicians’ Practice Patterns Dictate Procedures

Michael O'Riordan

November 20, 2018

News Conference News AHA 2018

Very EARLY Invasive Angiography in NSTE ACS Patients Reduces Risk of Recurrent Ischemia

Michael O'Riordan

November 11, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2018

Caitlin E. Cox

April 30, 2018

News Daily News

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

Michael O'Riordan

August 14, 2017

News Daily News

ICTUS: No Benefit at 10 Years With Early Invasive Strategy in NSTE ACS Patients

Michael O'Riordan

April 11, 2017

$The Coronary Sinus Reducer: A Device Based Therapy for Refractory Angina$

Presentation JIM 2017

The Coronary Sinus Reducer: A Device Based Therapy for Refractory Angina

Presenter: Francesco Giannini

February 10, 2017

News Industry News

Angionetics' Generx® [Ad5FGF-4] Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery Disease

September 12, 2016

News Daily News

Early Invasive Intervention Trumps Delayed Approach in NSTEMI Patients

Michael O'Riordan

January 20, 2016

News Industry News

Cardiome Submits Supplemental New Drug Submission (sNDS) For AGGRASTAT To Health Canada

July 22, 2015

News Daily News

Real-World Study Shows Benefits of Treating Culprit Vessel Only in STEMI

Yael L. Maxwell

November 06, 2014

Advertisement

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Intermittent Coronary Sinus Occlusion Fails to Cut Infarct Size in STEMI

NY State to Exclude Emergency PCI Deaths From Physician-Level Public Reports

CV Care Around Noncardiac Surgery: New ESC Guidelines

Gatekeeper CTA Strategy in Stable Chest Pain Still Needs Honing

New European NSTE ACS Guidelines Embrace hs-Troponin, CTA, NOAC Trials

July 2020 News Roundup

Recurrent Events Common Among Young Patients With CAD

Best Strategy Questioned for NSTE ACS Patients With Prior CABG

Staged PCI or Complete Revasc? Physicians’ Practice Patterns Dictate Procedures

Very EARLY Invasive Angiography in NSTE ACS Patients Reduces Risk of Recurrent Ischemia

TCTMD’s Top 10 Most Popular Stories for April 2018

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

ICTUS: No Benefit at 10 Years With Early Invasive Strategy in NSTE ACS Patients

The Coronary Sinus Reducer: A Device Based Therapy for Refractory Angina

Angionetics' Generx® [Ad5FGF-4] Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery Disease

Early Invasive Intervention Trumps Delayed Approach in NSTEMI Patients

Cardiome Submits Supplemental New Drug Submission (sNDS) For AGGRASTAT To Health Canada

Real-World Study Shows Benefits of Treating Culprit Vessel Only in STEMI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content